AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Morgan Stanley on Amgen (AMGN): 'We believe the acquisition will be viewed as a modest positive'
August 4, 2022 10:03 AM EDTMorgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $253.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "We believe the acquisition will be viewed as a modest positive given investors are looking for mgt. to expand the pipeline and near-term revenues.... More
ChemoCentryx (CCXI) to Resume Trading at 8:30 a.m.
August 4, 2022 8:07 AM EDTChemoCentryx (NASDAQ: CCXI) to Resume Trading at 8:30 a.m.
... More